Thus, CAR T cells targeting C1QBP may serve as a therapeutic option for glioblastoma patients through specifically recognizing and eliminating C1QBP expressing glioma cells and tumor derived endothelial cells, finally controlling tumor growth in orthotopic syngeneic and xenograft mouse models. Here, C1QBP is linked to neoplasm.